I-131 Use In Nuclear Medicine: Mechanisms, Safety, And Protocols

20 Questions | Total Attempts: 1216

SettingsSettingsSettings
Please wait...
I-131 Use In Nuclear Medicine: Mechanisms, Safety, And Protocols

The following learning assessment is for the maiCE article I-131 Use in Nuclear Medicine: Mechanisms, Safety, and Protocols. First, open the CE article by clicking here. Then, complete the assessment by entering your name and email and selecting "Start" below. This CE activity is worth 1. 0 Category A CE credit (RCEEM AHRA), accepted by the ARRT and the NMTCB. A score of 75% or greater must be scored to obtain credit.   Your Certificate of CE Completion will be emailed to the address you use to register this test.   Your name will appear on your Certificate of CE Completion as you enter it below. Please include the full name you would like on your certificate as well as any credentials.


Questions and Answers
  • 1. 
    The clinical properties of I-131 are due to what?
    • A. 

      Half-life of the isotope

    • B. 

      Size of the isotope

    • C. 

      Gamma-radiation emitted by the isotope

    • D. 

      Beta-particles emitted by the isotope

    • E. 

      Method of delivery of the isotope

  • 2. 
    The half-life of I-131 is approximately
    • A. 

      8 seconds

    • B. 

      8 minutes

    • C. 

      8 days

    • D. 

      8 months

    • E. 

      8 years

  • 3. 
    What type of radiation does I-131 emitt? 
    • A. 

      Alpha

    • B. 

      Beta

    • C. 

      Gamma

    • D. 

      A & b

    • E. 

      B & c

  • 4. 
    I-131 is taken up by thyroid tissue in the body because iodine is a constituent of thyroid ___________ .
    • A. 

      Tissue

    • B. 

      Secretion

    • C. 

      Hormone

    • D. 

      Enzyme

  • 5. 
    Approximately what amount of I-131 in the bloodstream is deposited in thyroid tissue? 
    • A. 

      10%

    • B. 

      20%

    • C. 

      30%

    • D. 

      40%

    • E. 

      50%

  • 6. 
    When did I-131 begin its use in treatment of thyroid cancer? 
    • A. 

      1930s

    • B. 

      1940s

    • C. 

      1950s

    • D. 

      1960s

    • E. 

      1970s

  • 7. 
    In addition to thyroid cancer, what is another indication for the use of I-131 therapy? 
    • A. 

      Thyroiditis

    • B. 

      Hyperthyroidism

    • C. 

      Hypothyroidism

    • D. 

      A & b

    • E. 

      B & c

  • 8. 
    Precautions to protect not only patients, but also the general public that come in contact with them, are taken because:
    • A. 

      I-131 radiation is detectable outside of the patient body as well as excreted through their body fluid

    • B. 

      Diseases that I-131 treat are communicable

    • C. 

      I-131 treatment can cause susceptibility to communicable disease

    • D. 

      All of the above

  • 9. 
    In what form is I-131 delivered for treatment? 
    • A. 

      Injectable fluid

    • B. 

      Pill

    • C. 

      Transdermal patch

    • D. 

      Radioactive seeds

    • E. 

      A & b

  • 10. 
    Which of the following are possible short-term risks of I-131 treatment?
    • A. 

      Swelling of salivary glands

    • B. 

      Nausea

    • C. 

      Stomach irritation

    • D. 

      Tenderness in the neck area

    • E. 

      All of the above

  • 11. 
    What agencies are responsible for regulating the clinical and environmental exposure to I-131?
    • A. 

      NRC

    • B. 

      EPA

    • C. 

      FDA

    • D. 

      WHO

    • E. 

      All of the above

  • 12. 
    Progressive imaging scans of I-131 treatment of thyroid cancer should show __________ in thyroid appearance/uptake. 
    • A. 

      Decrease

    • B. 

      Increase

    • C. 

      No change

  • 13. 
    Thyroid cancer is most often found in ________ persons.
    • A. 

      Older

    • B. 

      Younger

    • C. 

      Obese

    • D. 

      A & b

    • E. 

      B & c

  • 14. 
    What disease is I-131 Tostitumomab indicated to treat? 
    • A. 

      Hodgkin's lymphoma

    • B. 

      Non-Hodgkin's lymphoma

    • C. 

      Grave's disease

    • D. 

      Multi-nodular goiter

    • E. 

      Hyperthyroidism

  • 15. 
    How many days does the NRC recommend a restriction in exposure to others for a patient who has undergone I-131 therapy with a dose of 70mCi?
    • A. 

      1 day

    • B. 

      2 days

    • C. 

      3 days

    • D. 

      5 days

    • E. 

      No restriction

  • 16. 
    A 2011 study specifically concerning 10 CFR 35.75 and I-131 patients sought to:
    • A. 

      Clarify the NRC's position on release of I-131 therapy patients

    • B. 

      Decrease the occurrence of thyroid cancer

    • C. 

      Identify the frequency of I-131 treatment

    • D. 

      Clarify the NRC's position on dosage of I-131 therapy patients

  • 17. 
    Pertaining to details surrounding release of patients after I-131 treatment, licensees must consider the ______________ .
    • A. 

      Extent of the patient's disease

    • B. 

      Destination of the patient after release

    • C. 

      Number of therapy sessions the patient has undergone

    • D. 

      All of the above

    • E. 

      None of the above

  • 18. 
    The NRC regulations regarding I-131 treatment are heavily reliant on the ___________ and their _________ .
    • A. 

      Patient; judgement

    • B. 

      Licensee; judgement

    • C. 

      Licensee; experience

    • D. 

      Patient; disease

    • E. 

      Patient; family

  • 19. 
    Why is I-131 therapy used in post-operative treatment of thyriod cancer? 
    • A. 

      To strengthen the thyroid tissue

    • B. 

      To ablate residual malignant cells

    • C. 

      For palliative treatment

    • D. 

      To treat metastasis

  • 20. 
    What is the 5-year survivial rate of thyroid cancer?
    • A. 

      57%

    • B. 

      67%

    • C. 

      97%

    • D. 

      45%

Back to Top Back to top